Feature | November 30, 2012

Study Examines Antiplatelet Effect of Clopidogrel and Prasugrel in Smokers and Nonsmokers

Results of the PARADOX study presented at TCT 2012

Clopidogrel Prasugrel TCT 2012 Smoking PARADOX Study Antiplatelet Therapy

November 30, 2012 — Results of a study investigating the effects of smoking on the antiplatelet medications clopidogrel and prasugrel were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Analyses from previous trials have demonstrated that nonsmokers receive less or no benefit from clopidogrel treatment as compared with smokers, who experience a clear treatment benefit. Clopidogrel and prasugrel are used in combination with aspirin to reduce blood clotting following an angioplasty or percutaneous coronary intervention (PCI). The PARADOX study is the first prospective, double-blind, placebo-controlled study comparing the pharmacokinetics and pharmacodynamics of clopidogrel versus prasugrel in smokers and nonsmokers.

Researchers randomized 54 nonsmokers and 54 smokers with stable coronary artery disease (CAD) on aspirin therapy to clopidogrel (75 mg daily for 10 days) or prasugrel (10 mg daily for 10 days) therapy and crossed-over after a 14-day washout. The co-primary objectives were the pharmacodynamics in clopidogrel-treated smokers versus clopidogrel-treated nonsmokers, and in prasugrel-treated smokers versus clopidogrel-treated smokers. Pharmacodynamics were assessed by the inhibition of platelet aggregation (IPA) as reported by the VerifyNow (VN)-P2Y12 assay.

Researchers found that clopidogrel-treated nonsmokers had lower device-reported IPA versus clopidogrel-treated smokers (mean treatment difference 7.7 percent; p=0.062), lower calculated IPA (mean treatment difference 9.1 percent; p=0.043), higher P2Y12 reaction units (mean treatment difference 36; p=0.005) and higher VASP-platelet reactivity index (mean treatment difference 7.6 percent; p=0.042). In addition, nonsmokers had lower clopidogrel active metabolite concentrations after adjustment for body weight than smokers. Prasugrel therapy was associated with a greater IPA and lower P2Y12 reaction units and VASP-platelet reactivity index compared to clopidogrel, regardless of smoking status (p<0.001 for all comparisons).

“Results from the PARADOX trial indicate that smoking influences the pharmacokinetics and pharmacodynamics of clopidogrel, but not of prasugrel. Nonsmokers had a reduced responsiveness to clopidogrel versus smokers, while prasugrel, compared to clopidogrel, had a greater antiplatelet effect regardless of smoking status,” said lead investigator Paul A. Gurbel, M.D. Gurbel is director of the Sinai Center for Thrombosis Research at the Sinai Hospital of Baltimore and an associate professor of medicine at Johns Hopkins University School of Medicine.

“The poorer antiplatelet response in clopidogrel-treated nonsmokers versus smokers may explain the inferior clinical benefit of clopidogrel in nonsmokers in major randomized trials, and deserves further investigation,” Gurbel said.

For more information: www.crf.org

Related Content

Million Hearts Cardiovascular Disease Risk Reduction Model, CMS, reduce heart attacks and strokes, participants
News | Patient Engagement| July 22, 2016
July 22, 2016 — The Centers for Medicare & Medicaid Services (CMS) recently announced 516 awardees in 47 states,
heart failure, after first heart attack, cancer risk, JACC study
News | Cardiac Diagnostics| July 21, 2016
People who develop heart failure after their first heart attack have a greater risk of developing cancer when compared...
Absorb, bioresorbable stent, BVS
Feature | Stents Bioresorbable| July 21, 2016 | Alphonse Ambrosia, D.O.
Some have labeled bioresorbable scaffolds (BRS), also known as bioresorbable stents, as the fourth revolution of inte
mitral valve surgery outcomes, twisting of the heart, echocardiography, NICSMR, JACC Basic to Translational Science
News | Heart Valve Technology| July 20, 2016
A novel study has found a simple pre-operative echocardiographic measurement of the amount of torsion of the heart...
TITAN II Trial, Carillon Mitral Contour System, Cardiac Dimensions, Open Heart journal, functional mitral regurgitation, FMR
News | Annuloplasty Rings| July 20, 2016
New data from the TITAN II trial confirm the safety and efficacy of the Carillon Mitral Contour System in the treatment...
Mitralign, Trialign system, tricuspid regurgitation. SCOUT U.S. study, phase 1 enrollment
News | Heart Valve Technology| July 19, 2016
Mitralign Inc. announced last week it has completed subject enrollment in the SCOUT early feasibility study in the...
Sponsored Content | Videos | Inventory Management| July 19, 2016
You have bigger priorities than managing inventory.
Abbott Absorb bioresorbable stent, dissolving BVS, first West Coast implant, Good Samaritan Hospital Los Angeles
News | Stents Bioresorbable| July 19, 2016
Good Samaritan Hospital, Los Angeles, is the first hospital on the West Coast to offer patients with coronary artery...
Medtronic, In.Pact Admiral drug coated balloon, DCB, FDA approval, 150 mm length
Technology | Drug-Eluting Balloons| July 18, 2016
Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for the IN.PACT Admiral drug-coated balloon...
3-D OCT

A 3-D OCT rendering of a stented vessel segment created on St. Jude Medical's Ilumien Optis OCT system. 

Feature | Angiography| July 15, 2016 | Dave Fornell
While angiographic X-ray fluoroscopy systems are the workhorse for transcatheter cardiovascular interventional proced
Overlay Init